Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HHS’ Adverse Drug Event Action Plan Calls For New Treatment Guidelines

This article was originally published in The Pink Sheet Daily

Executive Summary

Draft recommends research and initiatives that could lead to changes in drug prescribing practices to reduce the likelihood of adverse drug events – and may even include more prescribing if adverse drug events can be mitigated.

You may also be interested in...



Improving Drug Safety – Without FDA: HHS Adverse Event Report Focuses On Other Agencies

HHS is declaring a priority of reducing the burden of adverse events associated with three large classes of drugs: opioids, antidiabetics, and anticoagulants. And, at least in its draft action plan, FDA is not the central actor.

HHS Seeks Industry Input On National Quality Strategy

HHS expects device and drug manufacturers, as well as other industry stakeholders, to provide ongoing feedback to aid the agency's development of its official National Quality Strategy for health care, the agency said in a March 21 report to Congress.

As FDA Advisers Grow Comfortable With EUAs, Harder Decisions On J&J’s Vaccine Fall To States, Individuals

J&J’s COVID-19 vaccine sails through its US FDA advisory panel, but that just means the subpopulation efficacy questions need to be wrestled with by other public health space, as CDC and the states must figure out the best way to distribute multiple vaccines with differing efficacy profiles, regimens and storage requirements.

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel